AZD4573 as Monotherapy or in Combinations with Anti-cancer Agents in Patients with r/r PTCL or r/r cHL

Study identifier:D8231C00001

ClinicalTrials.gov identifier:NCT05140382

EudraCT identifier:2021-002570-54

CTIS identifier:N/A

Recruitment Complete

Official Title

A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination with Anti-cancer Agents in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma or classical Hodgkin Lymphoma

Medical condition

Relapsed/refractory Peripheral T-cell Lymphoma

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD4573

Sex

All

Actual Enrollment

52

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 15 Dec 2021
Primary Completion Date: 25 Aug 2023
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria